Clinical trial · Observational
The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer
The Relationship Between Complement C3 Depletion and Metastatic Gastric Cancer: A Prospective Pilot Study
NCT02425930CI-TRIAL-00017646completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to investigate whether complement C3 depletion is associated with poor short-term outcomes in postoperative patients with gastric cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Complement Component Deficiency | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gastrectomy plus D2 lymphadenectomy | Procedure | — | UNRESOLVED |
| S-1+Oxaliplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- C3 Depletion
- description
- Patients with persistent low-level of complement C3 within the perioperative period would be assigned into this main observational group. After a careful multidisciplinary treatment (MDT) discussion, a radical operation with gastrectomy plus D2 lymphadenectomy would be performed, followed by an adjuvant chemotherapy if required. Generally, SOX chemo regimen (S-1+Oxaliplatin) would be first considered for the candidates.
- interventionNames
- Procedure: gastrectomy plus D2 lymphadenectomy
- Drug: S-1+Oxaliplatin
- label
- Non-C3 depletion
- description
- Patients with normal plasma values of complement C3 within the perioperative period would be assigned into this control group. Those patients would undergo the same decision making process to determine the final treatment plan.
- interventionNames
- Procedure: gastrectomy plus D2 lymphadenectomy
- Drug: S-1+Oxaliplatin
Primary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological diagnosis of gastric adenocarcinoma * Radical operation and adjuvant chemotherapy endurable * Informed consent approved Exclusion Criteria: * Age \<18 or \>75 years old * Pregnancy or lactating woman * Any primary diagnosis other than gastric cancer * Confirmed complement deficiency due to immunity dysfunction or other disease * Required blood transfusion, plasmapheresis, or emergent operation
References
Publications (1)
- DERIVEDYuan K, Ye J, Liu Z, Ren Y, He W, Xu J, He Y, Yuan Y. Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression. J Exp Clin Cancer Res. 2020 Jan 13;39(1):9. doi: 10.1186/s13046-019-1514-3. PMID 31928530